证券代码：600267 证券简称：海正药业 公告编号：临 2026-15 号 浙江海正药业股份有限公司 关于替格瑞洛原料药获得 CEP 证书的公告 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量 管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称 "EDQM"）签发的替格瑞洛原料药欧洲药典适用性认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP 证书"）， 现就相关情况公告如下： 一、CEP证书相关信息 二、药品的其他相关情况 替格瑞洛适用于急性冠状动脉综合征（ACS）的治疗，降低ACS患者或有心 肌梗塞（MI）病史患者的心血管死亡、心肌梗死和卒中的发生率，原研厂家为 阿斯利康。目前，国内外替格瑞洛原料药的主要生产、销售厂商有INTAS、浙江 海正药业 ...

格隆汇2月24日丨海正药业(600267.SH)公布，公司收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发的替格瑞洛原料药欧洲药典适用性认证 证书（Certificate ofSuitability to Monograph of European Pharmacopoeia，以下简称"CEP 证书"），替格瑞 洛适用于急性冠状动脉综合征（ACS）的治疗，降低ACS患者或有心肌梗塞（MI）病史患者的心血管 死亡、心肌梗死和卒中的发生率，原研厂家为阿斯利康。 本次公司替格瑞洛原料药获得CEP认证证书，显示欧洲规范市场对该原料药质量的认可和肯定，标志此 产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积 极的影响。 ...

海正药业公告称，公司收到欧洲药品质量管理局签发的替格瑞洛原料药欧洲药典适用性认证证书。该证 书的获得标志着该产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓 展国际市场带来积极影响。替格瑞洛适用于急性冠状动脉综合征的治疗，原研厂家为阿斯利康。2024年 全球销售量约为171,705.29公斤，2025年1-9月全球销售量约为143,714.60公斤。公司于2023年12月28日 向EDQM提交申请，并于近日收到CEP证书。 ...

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 厦门信达 | 000701 | 股权激励限售流通 | 12.9万 | | 兖矿能源 | 600188 | 股权激励限售流通 | 2960.32万 | | 海正药业 | 600267 | 股权激励限售流通 | 73.13万 | | 苏泊尔 | 002032 | 股权激励限售流通 | 3.95万 | | 航天彩虹 | 002389 | 股权激励限售流通 | 270.57万 | | 晓鸣股份 | 300967 | 股权激励限售流通 | 59.53万 | | 蕾奥规划 | 300989 | 股权激励限售流通 | 35.64万 | | 丛麟科技 | 688370 | | 9335.88万 | 今日具体限售解禁股情况如下： 智通财经APP获悉，2月24日共有8家上市公司的限售股解禁，解禁总市值约25.23亿元。 ...

Group 1 - The 1-year and 5-year LPR will be announced on February 24, with the current rates remaining unchanged at 3.0% and 3.5% respectively, marking the eighth consecutive month of stability [2] - The domestic refined oil price adjustment window will open on February 24, following a previous increase of 205 CNY/ton for gasoline and 195 CNY/ton for diesel on February 3 [3] Group 2 - The MSCI China Index will undergo adjustments effective February 27, 2026, including the addition of 37 stocks and the removal of 16 stocks [4] - Apple Inc. will hold its annual shareholder meeting on February 24, focusing on new product development, AI technology implementation, and supply chain adjustments [5] Group 3 - A total of 56.43 billion shares of restricted stocks will be released in the A-share market from February 24 to 27, with a market value exceeding 87 billion CNY [6] - Notable companies with significant restricted stock releases include Huaxi Nonferrous and *ST Songfa, each exceeding 10 billion CNY in market value [6] Group 4 - Two new stocks will be issued in the week following the holiday, with Hai Fei Man on February 24 and Gu De Electric Materials on February 25 [8]

Group 1 - The core point of the article is that Haizheng Pharmaceutical (600267) has filed an international patent application for a compound named "Aromatic and Cyclic Derivatives and Their Preparation Methods and Uses" with the application number PCT/CN2025/112321, which is set to be published internationally on February 12, 2026 [1] - In 2023, Haizheng Pharmaceutical has announced a total of four international patent applications [1] - The company invested 202 million yuan in research and development in the first half of 2025, representing a year-on-year increase of 13.98% [1]

过去的2025年，既非生物医药的寒冬，也未被产业泡沫裹挟；更不是只谈买卖、单纯依靠管线出海兑现以求生存的一年，而是生物医药产业逐步回归理性价 值与长期主义的一年。 对我们而言，AI之于生物医药，远不止是降本增效的工具，更是在源头创新上打开了全新的空间。通过AI，我们能够探索以往人类经验难以触达的新靶 点，设计结构更为精妙的分子。AI正在加速打破新药研发"双十定律"（十年、十亿美金）的束缚，让那些曾被认为不可成药的靶点成为可能。 展望2026年，对英矽智能来说，更重要的是持续拓展更广阔的边界，包括生命科学周边领域与新分子实体的探索。例如，我们近期宣布在宜兴建立AI驱动 的自动化多肽筛选实验平台。同时，BD仍将是我们的主旋律，我们期待更多管线在不同阶段与合作伙伴达成研发合作。此外，我们近期提出MMAI Gym框 架，期待赋能LLM在垂直领域的专精能力训练。 （经济观察报 记者 张铃） 2025年对英矽智能而言同样收获颇丰。我们实现了靶向KIF18A的肿瘤项目、靶向PHD1/2的肾性贫血项目两条管线的全部或部分对外授权；推动了与礼来、 施维雅、海正药业、复星医药等跨国或大型制药公司的研发合作；并在6个临床项目与5个 ...

Group 1 - The core viewpoint of the articles emphasizes that 2025 was a year of rational value and long-termism for the biopharmaceutical industry, rather than a winter or bubble phase [1] - The company achieved significant milestones, including the successful listing on the Hong Kong Stock Exchange on December 30, 2025, becoming the largest biotech company by financing scale in the Hong Kong market that year [1] - The company established collaborations with major pharmaceutical firms such as Eli Lilly, Sihuan Pharmaceutical, and Fosun Pharma, and made progress in clinical and preclinical projects [1] Group 2 - In the AI pharmaceutical sector, AI has transitioned from being viewed as a "black box" to a foundational element, with more pharmaceutical companies adopting and deploying AI technologies [2] - The company has gained trust from the industry and partners through its benchmark capabilities in AI drug development and continuous output of preclinical candidates [2] - Looking ahead to 2026, the company aims to expand into broader life sciences areas and explore new molecular entities, including the establishment of an AI-driven automated peptide screening platform [2]

Core Insights - The article highlights the significant presence of Chinese brands at the Milan Winter Olympics, showcasing their commitment to sports culture and international exchange [1][2]. Group 1: Event Highlights - The "China Night" event, hosted by Mengniu and guided by the Chinese Olympic Committee, aimed to promote Chinese sports culture and the Olympic spirit [1]. - The "Li Ning Night" event featured a special exhibition showcasing advancements in sports technology, aesthetics, and environmental practices [1]. Group 2: Brand Participation - Chinese companies like Mengniu and TCL are competing in the commercial arena of the Olympics, leveraging their product quality and technology to gain international recognition [2]. - Mengniu, as the first global Olympic partner in the dairy industry, emphasizes the synergy between sports and nutrition, aligning its brand spirit with Olympic values [4]. Group 3: Sponsorship Dynamics - The "TOP sponsors" represent the pinnacle of Olympic sponsorship, with fierce competition among brands to secure these positions [3]. - TCL's involvement as a new "TOP sponsor" at the Milan Winter Olympics includes providing advanced display technology for broadcasting [3]. Group 4: Apparel and Innovation - Li Ning has become the official sportswear partner for the Chinese Olympic Committee, introducing innovative designs and materials for the athletes' outfits [6]. - The outdoor award outfits feature advanced sports technology, emphasizing performance and sustainability through the use of recycled materials [7]. Group 5: Future Outlook - The upcoming 2026 sports events, including the World Cup, are expected to intensify competition among sports brands for marketing opportunities [7]. - Long-term planning and consistent brand influence are essential for companies aiming to leverage sports sponsorship effectively [7].

Group 1 - The State Council will hold a press conference regarding the "Accelerating the Cultivation of New Growth Points in Service Consumption Work Plan" on February 6 at 3 PM [1] Group 2 - On February 6, a total of 7 companies will have their restricted shares unlocked, with a total unlock volume of 33.61 million shares, amounting to a market value of 5.243 billion yuan [2] - The companies with the highest unlock volumes are Xinghuan Technology-U, Dengkang Dental, and Hansan Technology, with unlock shares of 27.16 million, 2.99 million, and 1.52 million respectively [2] - In terms of unlock market value, Xinghuan Technology-U, Dengkang Dental, and Hansan Technology lead with values of 4.985 billion yuan, 130 million yuan, and 8.616 million yuan respectively [2] Group 3 - Eight companies disclosed stock repurchase progress on February 6, with 2 companies announcing new repurchase plans, 2 companies having their plans approved by shareholders, and 4 companies completing their repurchase plans [3] - The newly announced repurchase plans include Haizheng Pharmaceutical and Huatong Cable, with intended repurchase amounts of up to 726,400 yuan and 296,800 yuan respectively [3] - The companies that received shareholder approval for their repurchase plans are Hengtong Co. and Hongtai Sun, with intended repurchase amounts of up to 100 million yuan and 215,000 yuan respectively [3]